HEXO Stock Delays the Release of Q2 Results: Should Investors Be Worried?

Can investors of HEXO Corp (TSX:HEXO)(NYSE:HEXO) rely on the accuracy of the company’s financials?

| More on:
Question marks in a pile

Image source: Getty Images

HEXO Corp (TSX:HEXO)(NYSE:HEXO) and other pot stocks have been erratic over the past several weeks. The markets as a whole have been unstable. And that’s made already volatile pot stocks even more of a roller-coaster ride of late.

HEXO is a shadow of the company it once was. It no longer has its aggressive $400 million sales forecast for fiscal 2020 and the excitement surrounding the stock has waned. Earlier this month, the company announced more bad news: it would be delaying the release of its second-quarter results and expects to record an impairment charge as well.

The company’s been busy restating and refiling financials

In early January, HEXO announced it had completed refiling and restating its year-end results for fiscal 2019. The company had to make corrections, including to its deferred tax liability that was overstated. Earlier this month, the company refiled its management discussion and analysis (MD&A) for fiscal 2019 as well as for the quarter ending October 31, 2019. News of another filing delay now in the second quarter is par for the course given the company’s recent track record.

This latest update also comes after HEXO announced in February that it would be changing its auditors, and that a member of its board of directors, Nathalie Bourque, was resigning in yet another high-profile departure. There is no reason given for the changes and to suggest any would be pure speculation.

It’s not unusual for a company to change auditors. But given the restatements, refilings, and now a “significant” write-down – expected to be as much as $280 million, according to BNN Bloomberg – things are not going smoothly at HEXO, to say the least.

Why should investors care?

It may seem like a lot of paperwork going on, and correcting and changing numbers, that’s taking place. But it could be a cause for concern. If a company’s financials are not correct then investors cannot rely on them. Knowing there may be an adjustment later on makes it harder to evaluate a company’s performance. And at this point, it would be hard to take HEXO’s financials at face value and assume that they will remain unchanged.

Should you consider buying HEXO stock today?

In the past year, HEXO’s stock has fallen around 90%. That’s a mammoth decline even in the pot sector where valuations have been cratering in recent months. But the danger is that HEXO’s shares can always go lower. A low share price shouldn’t be the reason to invest in the company. And investors shouldn’t ignore the problems relating to the company’s financials. They may be signs of poor governance and controls.

Someone inputting the wrong number on a balance sheet or income statement doesn’t mean that HEXO can’t efficiently grow pot or that there’s no market for its products. But it could be symptomatic of a company that isn’t running a tight ship. And at a time when investors are carefully looking at which cannabis companies are safe buys and still investable, any hint that a company may be shirking its responsibilities can send the stock into the gutter.

HEXO may be a tempting buy due to its low price. However, investors are better off waiting for the company to show some consistency and reliability in its quarterly reports before making any investment decision.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor David Jagielski has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »